MX2023008096A - Nuevas cargas utiles de esteroides, enlazadores de esteroides, adc que los contienen y uso de estos. - Google Patents

Nuevas cargas utiles de esteroides, enlazadores de esteroides, adc que los contienen y uso de estos.

Info

Publication number
MX2023008096A
MX2023008096A MX2023008096A MX2023008096A MX2023008096A MX 2023008096 A MX2023008096 A MX 2023008096A MX 2023008096 A MX2023008096 A MX 2023008096A MX 2023008096 A MX2023008096 A MX 2023008096A MX 2023008096 A MX2023008096 A MX 2023008096A
Authority
MX
Mexico
Prior art keywords
cells
adcs
human
vista
antibody
Prior art date
Application number
MX2023008096A
Other languages
English (en)
Inventor
Xin Huang
Michael Molloy
Yalin Guo
Jay Rothstein
Dov Pechenick
Toni Kline
Sergey Seregin
Julio Medina
Kierstin Bell
Catherine Carriere
Anna Kuta
Nicholas Schwertner
Maria Day
Shibhani Rajanna
Jieyu Zhou
Erin Clark
Labros Meimetis
Sheng Sun
Alexander Koval
Sravan Thummanapelli
Dmitry Borkin
Rajeshkumar Maganlal Loriya
Yingcai Wang ( Ian)
Original Assignee
Immunext Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunext Inc filed Critical Immunext Inc
Publication of MX2023008096A publication Critical patent/MX2023008096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona nuevos glucocorticosteroides, enlazadores de glucocorticosteroides y conjugados de anticuerpo y fármaco (ADC) que comprenden un anticuerpo o fragmento de anticuerpo que se une a un antígeno expresado en células inmunitarias, opcionalmente un antígeno expresado en células inmunitarias humanas. En algunos casos, los ADC comprenden un anticuerpo anti-VISTA humano (supresor de la activación de células T que contiene inmunoglobulina de la región V (1)) o un fragmento de anticuerpo de unión al antígeno anti-VISTA que se une a las células que expresan VISTA a un pH fisiológico que tiene una semivida sérica corta (˜ 24-72 o 24-48 o 12-24 horas o menos en un roedor con activación de VISTA humano o (˜ 1-3.5 días o menos en un primate humano o no humano). En algunos casos, estos ADC en cuestión tienen un inicio de acción rápido y son potentes durante un período prolongado, ya que las células inmunitarias los internalizan de manera muy eficaz en grandes cantidades, donde se escinden y liberan grandes cantidades de carga útil de esteroides activos. La invención también se refiere al uso de tales ADC y nuevos esteroides para el tratamiento de afecciones autoinmunitarias, alérgicas e inflamatorias. La invención se refiere además a métodos para reducir los efectos secundarios adversos y/o mejorar la eficacia de los agonistas del receptor de glucocorticoides mediante el uso de dichos ADC para administrar de forma selectiva estos agentes antiinflamatorios a las células inmunitarias diana, como monocitos, neutrófilos, células B, células T, Treg, eosinófilos, células NK, macrófagos, células mieloides, et al., y particularmente células mieloides, reduciendo así la toxicidad potencial en células no diana.
MX2023008096A 2021-01-07 2022-01-07 Nuevas cargas utiles de esteroides, enlazadores de esteroides, adc que los contienen y uso de estos. MX2023008096A (es)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202163134811P 2021-01-07 2021-01-07
US202163138958P 2021-01-19 2021-01-19
US202163178378P 2021-04-22 2021-04-22
US202163186447P 2021-05-10 2021-05-10
US202163188499P 2021-05-14 2021-05-14
US202163246941P 2021-09-22 2021-09-22
US202163251939P 2021-10-04 2021-10-04
US202163271023P 2021-10-22 2021-10-22
US202163271554P 2021-10-25 2021-10-25
US202163284886P 2021-12-01 2021-12-01
US202163290100P 2021-12-16 2021-12-16
PCT/US2022/011687 WO2022150637A1 (en) 2021-01-07 2022-01-07 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF

Publications (1)

Publication Number Publication Date
MX2023008096A true MX2023008096A (es) 2023-09-22

Family

ID=82358345

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008096A MX2023008096A (es) 2021-01-07 2022-01-07 Nuevas cargas utiles de esteroides, enlazadores de esteroides, adc que los contienen y uso de estos.

Country Status (10)

Country Link
EP (1) EP4271387A1 (es)
JP (1) JP2024502360A (es)
KR (1) KR20230144129A (es)
AU (1) AU2022205664A1 (es)
BR (1) BR112023013247A2 (es)
CA (1) CA3203533A1 (es)
IL (1) IL304059A (es)
MX (1) MX2023008096A (es)
TW (1) TW202241451A (es)
WO (1) WO2022150637A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4308170A1 (en) 2021-03-18 2024-01-24 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CN117500816A (zh) * 2021-08-26 2024-02-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
TW202327620A (zh) * 2021-09-14 2023-07-16 大陸商映恩生物製藥（蘇州）有限公司 一種抗炎症的化合物及其用途
WO2024125639A1 (zh) * 2022-12-16 2024-06-20 津药生物科技（天津）有限公司 新型糖皮质激素、其制备方法及用途
WO2024140838A1 (zh) * 2022-12-28 2024-07-04 映恩生物制药（苏州）有限公司 抗bdca2抗体-药物偶联物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139369A (en) * 2010-02-05 2011-11-16 Chiesi Farma Spa Pyrrolidine derivatives
DK3464318T3 (da) * 2016-06-02 2021-06-28 Abbvie Inc Glucocorticoidreceptoragonist og immunkonjugater deraf

Also Published As

Publication number Publication date
IL304059A (en) 2023-08-01
TW202241451A (zh) 2022-11-01
BR112023013247A2 (pt) 2023-10-03
EP4271387A1 (en) 2023-11-08
AU2022205664A1 (en) 2023-08-17
WO2022150637A1 (en) 2022-07-14
CA3203533A1 (en) 2022-07-14
KR20230144129A (ko) 2023-10-13
JP2024502360A (ja) 2024-01-18

Similar Documents

Publication Publication Date Title
MX2023008096A (es) Nuevas cargas utiles de esteroides, enlazadores de esteroides, adc que los contienen y uso de estos.
Wang et al. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events
JP5951615B2 (ja) Ｔｌｒアゴニストの治療用途および組み合わせ治療
Brandish et al. Development of anti-CD74 antibody–drug conjugates to target glucocorticoids to immune cells
Van den Bosch et al. Targeting the monocyte–macrophage lineage in solid organ transplantation
Onrust et al. Basiliximab
KR101033196B1 (ko) 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
DE69216899T2 (de) Zytomodulierte Konjugate enthaltend spezifische Bindungspaargliedern
JP2007197464A (ja) 細胞および血清タンパク質アンカー並びに接合体
JP2022530089A (ja) 抗ｃｄ４５抗体薬物結合体とその利用法
Paz et al. Antifibrosis: to reverse the irreversible
AU2011235328A1 (en) Antibody-based depletion of antigen-presenting cells and dendritic cells
US20130078243A1 (en) Conjugate molecule
JP2016519111A5 (es)
EP3877415A1 (en) Methods for allogeneic hematopoietic stem cell transplantation
Bhattacharya et al. A novel pancreatic β-cell targeting bispecific-antibody (BsAb) can prevent the development of type 1 diabetes in NOD mice
Bhatt et al. CD30 and CD30-targeted therapies in Hodgkin lymphoma and other B cell lymphomas
Burke et al. Antibody–drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin
Burke et al. Glucuronide-linked antibody–tubulysin conjugates display activity in MDR+ and heterogeneous tumor models
Griffin et al. Worked to the bone: antibody-based conditioning as the future of transplant biology
Van Lier et al. Sex differences in cortisol secretion after administration of an ACTH analogue in sheep during the breeding and non-breeding season
Pretto et al. In vivo safety testing of Antibody Drug Conjugates
Arndt et al. CD8+ CD122+ PD-1− effector cells promote the development of diabetes in NOD mice
Powell et al. Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism
Song et al. Feasibility of localized immunosuppression: 3. Preliminary evaluation of organosilicone constructs designed for sustained drug release in a cell transplant environment using dexamethasone